Autor(es): Francois, Clement ; Gawlik, Gabriela ; Mestre-Ferrandiz, Jorge ; Pana, Adrian ; Perelman, Julian ; Yfantopoulos, John ; Simoens, Steven
Data: 2023
Identificador Persistente: http://hdl.handle.net/10362/159723
Origem: Repositório Institucional da UNL
Assunto(s): competition; Europe; generic medicines; pricing; sustainability; Pharmacology; Pharmacology (medical)
Funding Information: This study was funded by Medicines for Europe. Funding Information: CF and GG worked for Creativ-Ceutical (Which has been taken over by Putnam PHMR) which received funding from Medicines for Europe to undertake the study. SS has previously held the EGA Chair “European policy towards generic medicines”. Publisher Copyright: Copyright © 2023 Francois, Gawlik, Mestre-Ferrandiz, Pana, Perelman, Yfantopoulos and Simoens.
Background: Price erosion of generic medicines over time as a result of existing pricing policies in combination with increasing operational costs of these products due to high inflation, undermine long-term sustainable competition in European off-patent medicines markets. Therefore, the aim of this study is to identify new potential pricing models for retail generic medicines in Europe, examine their pros and cons, and illustrate them with examples inside or outside the pharmaceutical sector. Methods: A targeted literature review, one-to-one interviews and a joint advisory board meeting with experts from five European countries were carried out to assess potential pricing models for generic medicines. Results: We identified ten pricing models that can be applied to generic medicines. The tiered pricing model is viewed as a sustainable solution ensuring competitiveness, but requires market monitoring using a supportive IT infrastructure. De-linking the price of generic medicines from that of the off-patent originator medicine prevents the originator from forcing generic medicines’ prices to unsustainable levels. Higher costs due to inflation can be compensated in the automatic indexation model. Other pricing models that have less implementation potential include the one-in-one/multiple-out model, tax credits, value-based pricing, volume for savings and guaranteed margin/fee models. The hypothecated tax and cost allocation models, which add a patient fee to generic medicines prices, are not likely to be socially acceptable. Conclusion: When considering a new pricing model for generic medicines, the impact on innovative medicines and the characteristics of the healthcare system in a given country need to be taken into account. Also, there is a need to continuously follow up the level of competition in off-patent medicines markets and to identify sustainability risks.
